Day: November 29, 2022

The Limestone Boat Company Announces Third Quarter 2022 Results

The Limestone Boat Company Announces Third Quarter 2022 Results

COLLINGWOOD, Ontario, Nov. 29, 2022 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (the “Company”) (TSXV: BOAT | OTCQB: LMSBF) – owner and builder of Aquasport Boats, Limestone® Boats and Boca Bay Boats – today reports its financial results for the three and nine months ended September 30, 2022 (“Q3 FY 2022″). All dollar amounts are in Canadian dollars unless otherwise noted. The Company’s complete Financial Statements and Management Discussion and Analysis for the three and nine months ended September 30, 2022 are available at www.sedar.com or on the Company’s website at www.limestoneboatcompany.com. Limestone has started to see the effects of management decisions taken in Q2 2022 concerning wholesale pricing and labour realignment with improvements in margin. These are attributable, in large part, to price increases...

Continue reading

<div>Field Trip Health & Wellness Provides Business Update And Reports Fiscal Second Quarter 2023 Results</div>

Field Trip Health & Wellness Provides Business Update And Reports Fiscal Second Quarter 2023 Results

Post-quarter end, launched a refreshed version of the Company’s award-winning app for psychedelic guidance, renamed ‘Field Trip’, to include a number of new features, such as offline access to music and meditations, higher bit-rate streaming and access to Field Trip’s therapeutic programs. In November, announced ‘Freedom by Field Trip™’, a first-of-its-kind, one-year hybrid ketamine therapy program blending psychedelic-assisted therapies with holistic wellness support to offer people the ability to participate in ketamine therapy at-home or in one of Field Trip’s locations. Post-quarter end, strengthened leadership team with the appointment of Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative Health. Field Trip generated revenues of $1.8 million during the quarter ended...

Continue reading

Water Ways Reports Q3 2022 Financial Results: Sales of CAD$12.1M and Net Profit of CAD$3.5M

Water Ways Reports Q3 2022 Financial Results: Sales of CAD$12.1M and Net Profit of CAD$3.5M

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“Water Ways” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producers, announces the filing of its Interim Financial Statements (the “Statements“) and Managements Discussion and Analysis (the “MD&A“) for the three and nine months periods ended September 30, 2022. A comprehensive discussion of Water Ways’ financial position and results of operations is provided in the MD&A, filed on SEDAR (www.sedar.com) Mr. Ohad Haber, CEO and Chairman of the Board of Water Ways states: “We are continuing to build and grow...

Continue reading

Exco Technologies Limited Announces Results for Fourth Quarter and Year Ended September 30, 2022

Exco Technologies Limited Announces Results for Fourth Quarter and Year Ended September 30, 2022

Consolidated fourth quarter Sales of $140.4 million compared to $106.4 million in the prior year Quarterly Net Income of $5.6 million and EPS of $0.14 EBITDA of $16.5 million compared to $15.3 million in the prior year quarter Growth strategy continues with $52.7 million in capital spending and $57.6 million in cash deployed for the Halex acquisition in fiscal 2022.    Quarterly dividend of $0.105 per common share to be paid December 30, 2022 TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Exco Technologies Limited (TSX-XTC, OTCQX-EXCOF) today announced results for its fourth quarter and year ended September 30, 2022. In addition, Exco announced a quarterly dividend of $0.105 per common share which will be paid on December 30, 2022 to shareholders of record on December 16, 2022. The dividend is an “eligible dividend” in accordance...

Continue reading

Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S., Intent to Consult with Employee Representatives for a Proposed Consolidation of Certain European and U.K. Sites, and Update on Site Optimization Plans in Process

Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S., Intent to Consult with Employee Representatives for a Proposed Consolidation of Certain European and U.K. Sites, and Update on Site Optimization Plans in Process

WEST LAFAYETTE, Ind., Nov. 29, 2022 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced plans to close two isolator facilities in Indianapolis, Indiana, and consolidate them with existing facilities in the U.S. The Company’s subsidiaries in France and the U.K. have also proposed a consolidation plan of two facilities in Gannat, France, and Blackthorn, Bicester U.K., into existing facilities.   The Company also provided an update on its previously announced site optimization plans in Virginia, Michigan, and Pennsylvania. Robert Leasure, Jr., Inotiv’s President and Chief Executive Officer, commented, “We...

Continue reading

Keith Tucker Appointed as Chief Executive Officer at Team, Inc.

Keith Tucker Appointed as Chief Executive Officer at Team, Inc.

SUGAR LAND, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) — Team, Inc.’s (NYSE: TISI) (“TEAM” or the “Company”) Board of Directors (“Board”) has unanimously appointed Keith Tucker as Chief Executive Officer effective as of November 22. Mr. Tucker had been serving as interim Chief Executive Officer since March 2022. “We are pleased to announce Keith’s appointment as Chief Executive Officer. With his strong operational background and extensive knowledge of our client base, Keith is the right person to lead Team,” said Michael Caliel, non-executive Chairman of Team, Inc.’s Board of Directors. “Over the last eight months as Interim CEO, Keith has taken decisive actions to improve financial results and enhance liquidity while establishing the groundwork for further performance improvement. Keith is a well-respected leader...

Continue reading

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

–Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting– –Clinical Collaboration Agreement Entered into with Merck for Evaluation of PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with first-line and refractory non-small cell lung cancer (NSCLC)– —Focused Clinical Development Goals on Producing Nine Phase 1b/Phase 2 Data Readouts in Multiple Tumor Types Over the Next Two Years– WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) — Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results...

Continue reading

<div>Atlas Air Worldwide Shareholders Approve Proposed Acquisition by Investor Group Led by Apollo, Together with J.F. Lehman & Company and Hill City Capital</div>

Atlas Air Worldwide Shareholders Approve Proposed Acquisition by Investor Group Led by Apollo, Together with J.F. Lehman & Company and Hill City Capital

Transaction Expected to Close in the First Quarter of 2023 PURCHASE, N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) — Atlas Air Worldwide (Nasdaq: AAWW) (“Atlas” or the “Company”), a leading global provider of outsourced aircraft and aviation operating services, today announced that its shareholders voted to approve the Company’s pending acquisition by an investor group led by funds managed by affiliates of Apollo Global Management, Inc. (“Apollo”, NYSE: APO), together with investment affiliates of J.F. Lehman & Company (“J.F. Lehman”) and Hill City Capital (“Hill City”) at its special meeting of shareholders held earlier today. “We are pleased to receive overwhelming support from Atlas Air Worldwide shareholders, who recognize this transaction provides compelling value to them while giving us the opportunity to execute our strategic...

Continue reading

Eargo, Inc. Welcomes Patient Square Capital As New Majority Owner Following Rights Offering

Eargo, Inc. Welcomes Patient Square Capital As New Majority Owner Following Rights Offering

SAN JOSE, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR) (“Eargo” or “the Company”), a medical device company on a mission to improve the quality of life of people with hearing loss, is pleased to announce today that Patient Square Capital (“Patient Square”) has become the majority equity owner of the Company. Patient Square’s equity ownership of Eargo resulted from the conversion of Patient Square’s senior secured convertible notes per its previously announced investment in June 2022 and following the recent closing of Eargo’s successful rights offering of common stock. Patient Square now holds approximately 316.4 million shares of Eargo, or approximately 76.3% of the Company’s outstanding common stock. As a result of the conversion of Patient Square’s convertible notes, Eargo currently has no debt for borrowed...

Continue reading

MDxHealth Provides Business Update

MDxHealth Provides Business Update

NEWS RELEASE – INSIDE AND REGULATED INFORMATION29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023. Select mdx reimbursement update Under the foundational LCD (Local Coverage Decision) process recently implemented by the Molecular Diagnostics Services (MolDX) Program administered by Palmetto GBA, all tests within an LCD-covered indication must submit a Technical Assessment (TA) for review and consideration. The indication for use of Select mdx is covered by Medicare’s foundational LCD Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.